Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2023-06-09 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and legal basis. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of regulatory filings that do not fit into specific categories like M&A or dividends, and is best classified as a general regulatory filing.
2023-06-09 Korean
증권신고서(지분증권) (2023.07)
Capital/Financing Update Classification · 100% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement for Equity Securities) filed with the Financial Services Commission of South Korea. It details a capital increase through a rights offering followed by a public offering of unsubscribed shares (주주배정 후 실권주 일반공모 유상증자). This document is a formal regulatory filing for capital raising activities, which falls under the 'Capital/Financing Update' category.
2023-06-09 Korean
투자판단관련주요경영사항(임상시험결과)(중등증 또는 중증 아토피 피부염이 있는 시험대상자에서 SCM-AGH의 안전성 및 유효성을 평가하는 무작위배정, 제1상/2상 임상시험 결과)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from SCM Lifescience regarding the results of a Phase 1/2 clinical trial for their drug candidate SCM-AGH. It details the trial methodology, objectives, and statistical outcomes, and outlines future plans for Phase 3 trials. This type of disclosure is a standard regulatory filing for material corporate events in South Korea (DART system), which falls under the 'Regulatory Filings' category as it is a specific announcement of clinical trial results.
2023-05-30 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, purpose (clinical trial results), and method of the meeting. It is a short notification (under 5,000 characters) announcing the event and the subsequent availability of materials, rather than the presentation itself. Therefore, it falls under the category of a regulatory announcement regarding an event or report publication.
2023-05-26 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for SCM Lifescience, Inc. (에스씨엠생명과학 주식회사) for the period of Q1 2023 (2023.01.01-2023.03.31). It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by major shareholders and special related parties, including the reason for the change (stock option grants). This type of filing is a mandatory disclosure of significant shareholding changes, which falls under the 'Major Shareholding Notification' category.
2023-04-03 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.